TGFβ/ACTIVIN-SMAD2/3-EZH2 cooperates with OCT4 and NANOG in self-renewing hPSCs to keep CDKIs in an epigenetically poised state for rapid activation. Upon the initiation of endoderm differentiation ...

CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...

Protein kinases are the molecular switches of the cell. They control growth, division, communication, and survival by attaching phosphate groups to other proteins. When these switches are stuck in the ...

DESTIN, Fla. — An increasing array of B-cell targeting approaches may aid clinicians in managing the cycles and flares of lupus, according to a speaker at the Congress of Clinical Rheumatology East ...

Advancing evidence-based NSCLC testing and treatment across academic and community-based settings. Final overall survival analysis for a phase 3 randomized trial comparing afatinib to chemotherapy in ...

Aerobic glycolysis dominates lesion bioenergetics, with lactate promoting histone lactylation, M2 macrophage polarization, ...

Schematic representation of different strategies targeting TGF-β signaling for liver fibrosis therapy. TGF-β signaling inhibitors hold important therapeutic potential for hepatic fibrosis. Although ...

• BTK inhibitors work by targeting and blocking the BTK enzyme, which is crucial for the survival and growth of cancerous B-cells in mantle cell lymphoma (MCL). This cuts off the cancer cell’s support ...

Your doctor will check your blood at regular intervals during treatment. When you start taking these medications, your doctor may do blood tests once every two weeks. After the first couple of visits, ...

• BTK inhibitors are a type of targeted therapy for mantle cell lymphoma that works by blocking a specific enzyme, BTK, which is crucial for the cancer cells’ survival and spread. This interference ...